ROCKET PHARMACEUTICALS INC (RCKT)
US77313F1066 - Common Stock
Taking everything into account, RCKT scores 2 out of 10 in our fundamental rating. RCKT was compared to 565 industry peers in the Biotechnology industry. RCKT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RCKT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year RCKT has reported negative net income.
RCKT had a negative operating cash flow in the past year.
RCKT had negative earnings in each of the past 5 years.
RCKT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of RCKT (-65.55%) is worse than 62.75% of its industry peers.
RCKT's Return On Equity of -78.26% is in line compared to the rest of the industry. RCKT outperforms 52.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.55% | ||
| ROE | -78.26% | ||
| ROIC | N/A |
ROA(3y)-39.2%
ROA(5y)-32.4%
ROE(3y)-44.12%
ROE(5y)-37.05%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RCKT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, RCKT has more shares outstanding
The number of shares outstanding for RCKT has been increased compared to 5 years ago.
RCKT has a better debt/assets ratio than last year.
2.2 Solvency
RCKT has an Altman-Z score of 5.16. This indicates that RCKT is financially healthy and has little risk of bankruptcy at the moment.
RCKT's Altman-Z score of 5.16 is amongst the best of the industry. RCKT outperforms 80.75% of its industry peers.
RCKT has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
RCKT has a worse Debt to Equity ratio (0.06) than 62.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.16 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
RCKT has a Current Ratio of 6.05. This indicates that RCKT is financially healthy and has no problem in meeting its short term obligations.
RCKT has a Current ratio of 6.05. This is in the better half of the industry: RCKT outperforms 62.03% of its industry peers.
A Quick Ratio of 6.05 indicates that RCKT has no problem at all paying its short term obligations.
The Quick ratio of RCKT (6.05) is better than 62.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.05 | ||
| Quick Ratio | 6.05 |
3. Growth
3.1 Past
RCKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.60%, which is quite good.
EPS 1Y (TTM)14.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 32.60% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1.73%
EPS Next 2Y4.98%
EPS Next 3Y12.89%
EPS Next 5Y32.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RCKT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCKT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RCKT's earnings are expected to grow with 12.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.98%
EPS Next 3Y12.89%
5. Dividend
5.1 Amount
RCKT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ROCKET PHARMACEUTICALS INC
NASDAQ:RCKT (11/22/2024, 8:01:25 PM)
After market: 14.1 -0.01 (-0.07%)14.11
+1.32 (+10.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.29B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.55% | ||
| ROE | -78.26% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.05 | ||
| Quick Ratio | 6.05 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)14.6%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y1.73%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y